Pharvaris N.V.
PHVSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other. The $2.44B market capitalization puts PHVS squarely in mid-cap range for its industry. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Market Cap
$2.44B
Beta
-2.34
P/E (TTM)
—
P/E (Fwd)
-12.49
EPS (TTM)
$-3.10
EPS (Fwd)
$-2.80
ROE
-73.0%
ROA
-42.3%
Cash
$247.0M
Total Debt
$738,891
Free CF
-$87.7M
52W Change
50.3%
Annual Financials
Cash vs Debt
With $247.0M in cash and $739K in debt, PHVS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$87.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -73.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of -2.34 suggests PHVS is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Pharvaris N.V. and its sector.